



A

Target Research-related Question Answering (TRQA) benchmark



B

Question: Which of the following AR mutations are associated with resistance to prostate cancer therapies?

A) F877L
B) T878A
C) G1010L
D) Y121S

Answer: A, B

Question: What are the clinical limitations of using RXR agonists to target A BCA1?

Answer: RXR agonists induce hypertriglyceridemia and off-target effects due to RXR's involvement in multiple nuclear receptor pathways.


Question: What drug combinations for Crohn's disease are under development as of April 2025, and what stages have they reached?

Answer: clarithromycin+clofazimine+rifabutin, Phase III; guselkumab+golimumab, Phase II


Question: What is the highest development stage achieved in China for drugs targeting TNF- α for Crohn's disease up to April 2025, and which drugs are in this stage?

Answer: Approved; infliximab and adalimumab

C



D



E

